Insulet Corporation (NASDAQ: PODD) and DexCom, Inc. (NASDAQ: DXCM)
announced today their intention to enable DexCom’s mobile App platform,
which is currently under development, to integrate data from Insulet’s
OmniPod System. This will be the first version of a mobile App that is
capable of incorporating glucose and other diabetes-related data from
patients’ devices and displaying the integrated data via a smartphone
App. This event also marks the start of DexCom's open architecture
approach to diabetes-related data which will include an “approved by
DexCom” indication to validate the authenticity of devices and Apps
integrating DexCom CGM data.
“Providing OmniPod users and their healthcare providers with easier
access to their management data is another key step in making diabetes a
smaller part of life,” said Duane DeSisto, President and Chief Executive
Officer of Insulet. “Through DexCom’s mobile App platform, OmniPod users
will have greater access to the data that is so essential for
understanding and improving diabetes management. We are proud to help
people with diabetes gain greater and easier control over their disease
and we remain dedicated to providing advancements that further this
mission.”
“More than ever, we believe that effective diabetes management depends
on timely and accurate data. That is why we are excited to complete
development of the App and integrate data from Insulet’s OmniPod
system,” said Terry Gregg, DexCom’s CEO.
About Insulet Corporation
Insulet Corporation (NASDAQ: PODD) is an innovative medical device
company dedicated to making the lives of people with diabetes easier.
Through its OmniPod Insulin Management System, Insulet seeks to expand
the use of insulin pump therapy among people with insulin-dependent
diabetes. The OmniPod is a revolutionary and easy-to-use tubeless
insulin pump that features just two parts and fully-automated cannula
insertion. Insulet’s subsidiary, Neighborhood Diabetes, is a leading
distributor for diabetes products and supplies, delivered through a high
touch customer service model. To read inspiring stories of people with
diabetes living their lives to the fullest with OmniPod, visit our
customer blog, Suite D: http://suited.myomnipod.com.
Founded in 2000, Insulet Corporation is based in Bedford, Mass. For more
information, please visit: http://www.myomnipod.com.
About DexCom, Inc.
DexCom, Inc. (www.dexcom.com),
headquartered in San Diego, California, is developing and marketing
continuous glucose monitoring systems for ambulatory use by patients and
by healthcare providers in the hospital.
DexCom’s Cautionary Statement Regarding Forward Looking Statements
DexCom is a medical device company with a limited operating history.
Successful commercialization of the company's products is subject to
numerous risks and uncertainties, including a lack of acceptance in the
marketplace by physicians and patients, the inability to manufacture
products in commercial quantities at an acceptable cost, possible delays
in the company's development programs, the inability of patients to
receive reimbursement from third-party payors and inadequate financial
and other resources. Certain of these risks and uncertainties, in
addition to other risks, are more fully described in the company's
quarterly report on Form 10-Q for the period ending March 31, 2014, as
filed with the Securities and Exchange Commission on May 1, 2014.
Insulet’s Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements
concerning Insulet's expectations, anticipations, intentions, beliefs or
strategies regarding the future, including those related to future
product development. These forward-looking statements are based on its
current expectations and beliefs concerning future developments and
their potential effects on Insulet. There can be no assurance that
future developments affecting Insulet will be those that it has
anticipated. These forward-looking statements involve a number of risks,
uncertainties (some of which are beyond its control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements. These risks and uncertainties include, but
are not limited to: risks associated with the Company's dependence on
its principal product, the OmniPod System; technological change and
product innovation adversely affecting the Company's business; potential
termination of Insulet's license to incorporate a blood glucose meter
into the OmniPod System or its inability to enter into new license
agreements; Insulet's ability to protect its intellectual property and
other proprietary rights; conflicts with the intellectual property of
third parties, including claims that Insulet's current or future
products infringe or misappropriate the proprietary rights of others;
adverse regulatory or legal actions relating to the OmniPod System; the
potential violation of federal or state laws protecting the
confidentiality of patient health information, or any challenge to or
investigation into Insulet's practices under these laws; product
liability lawsuits that may be brought against Insulet; and other risks
and uncertainties described in its Annual Report on Form 10-K, which was
filed with the Securities and Exchange Commission on February 28,
2014 in the section entitled "Risk Factors," and in its other filings
from time to time with the Securities and Exchange Commission. Should
one or more of these risks or uncertainties materialize, or should any
of its assumptions prove incorrect, actual results may vary in material
respects from those projected in these forward-looking
statements. Insulet undertakes no obligation to publicly update or
revise any forward-looking statements.
Copyright Business Wire 2014